Cara Therapeutics Inc (CARA)
0.2811
-0.01
(-3.24%)
USD |
NASDAQ |
Nov 05, 11:30
Cara Therapeutics Research and Development Expense (Annual): 108.51M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 108.51M |
| December 31, 2022 | 91.88M |
| December 31, 2021 | 82.70M |
| December 31, 2020 | 107.85M |
| December 31, 2019 | 113.82M |
| December 31, 2018 | 75.53M |
| December 31, 2017 | 48.52M |
| Date | Value |
|---|---|
| December 31, 2016 | 49.25M |
| December 31, 2015 | 21.22M |
| December 31, 2014 | 15.07M |
| December 31, 2013 | 8.685M |
| December 31, 2012 | 4.597M |
| December 31, 2011 | 7.159M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
82.70M
Minimum
2021
113.82M
Maximum
2019
100.95M
Average
107.85M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Alaunos Therapeutics Inc | 16.28M |
| Oragenics Inc | 15.49M |
| Cocrystal Pharma Inc | 15.17M |
| Citius Pharmaceuticals Inc | 14.82M |